CTA
VRTX icon

Chesley Taft & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Chesley Taft & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$537K Buy
1,082
+213
+25% +$94.4K 0.02% 273
2026
Q1 		$388K Buy
869
+87
+11% +$40.6K 0.02% 299
2025
Q4 		$355K Buy
782
+219
+39% +$94.4K 0.01% 309
2025
Q3 		$220K Sell
563
-33
-6% -$13.8K 0.01% 338
2025
Q2 		$265K Buy
596
+110
+23% +$50.7K 0.01% 310
2025
Q1 		$236K Buy
+486
New +$226K 0.01% 320
2021
Q4 		– Sell
-3,154
Closed -$572K – 303
2021
Q3 		$572K Sell
3,154
-660
-17% -$129K 0.03% 221
2021
Q2 		$769K Hold
3,814
– – 0.04% 197
2021
Q1 		$821K Sell
3,814
-4,575
-55% -$1M 0.05% 182
2020
Q4 		$1.98M Sell
8,389
-3,050
-27% -$700K 0.13% 124
2020
Q3 		$3.11M Buy
11,439
+1,682
+17% +$464K 0.22% 92
2020
Q2 		$2.83M Buy
9,757
+7,740
+384% +$2.1M 0.22% 93
2020
Q1 		$480K Sell
2,017
-25
-1% -$5.74K 0.04% 188
2019
Q4 		$447K Buy
2,042
+493
+32% +$99.8K 0.03% 216
2019
Q3 		$262K Buy
+1,549
New +$274K 0.02% 243

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Chesley Taft & Associates's VRTX Position: Q2 2026 in Review

Chesley Taft & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, buying an estimated $94.4K and bringing the position to 1,082 shares worth $537K. The position accounts for 0.02% of the portfolio, ranked #273.

Chesley Taft & Associates first reported a position in VRTX in Q3 2019 and has held it in 15 quarters since. The position peaked at $3.11M in Q3 2020. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Chesley Taft & Associates held 1,082 shares of Vertex Pharmaceuticals worth $537K as of Q2 2026.
  • Chesley Taft & Associates bought 213 Vertex Pharmaceuticals shares in Q2 2026, an estimated $94.4K.
  • Vertex Pharmaceuticals made up 0.02% of Chesley Taft & Associates's portfolio in Q2 2026, its #273 holding.
  • Chesley Taft & Associates first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 15 quarters since.
  • Chesley Taft & Associates's Vertex Pharmaceuticals position peaked at $3.11M in Q3 2020.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.